胆补充剂与阿尔茨海默病风险之间的关联:系统审查协议
Sixtus Aguree1, Maryam Zolnoori2, Thea Patricia Atwood3
1Department of Applied Health Science, School of Public Health, Indiana University Bloomington, Bloomington, IN, United States.
这一系统性审查检查了老年人胆摄入量和阿尔茨海默病 (AD) 风险. 证据是混合的,强调需要进一步的研究来澄清胆在认知健康和AD预防中的作用.
科学领域:
- 营养科学 营养科学
- 神经科学是一个神经科学.
- 老年学是指老年学的学科.
背景情况:
- 越来越多的证据表明,老年人胆摄入量和认知功能之间存在联系.
- 然而,研究表明,胆对阿尔茨海默病 (AD) 进展和认知能力改善的影响存在矛盾.
研究的目的:
- 系统地审查和评估胆补充剂对阿尔茨海默病风险的比较临床有效性.
- 总结有关65岁以上成年人胆摄入量和AD之间关系的现有证据.
主要方法:
- 在多个电子数据库 (PubMed,MEDLINE,EMBASE,CINAHL,Scopus,Cochrane,Web of Science) 进行全面的文献搜索,直到2023年10月.
- 将包括比较65岁以上阿尔茨海默病患者在不同时间点测量胆生物标志物的研究,并遵守PRISMA指南.
- 偏差风险将使用Covidence软件进行评估.
主要成果:
- 该审查将综合临床试验和准实验证据,分析老年人胆摄入量和阿尔茨海默病风险.
- 结果将以描述性的形式呈现,详细说明研究特征,批判性评估结果和主要结果.
结论:
- 这一系统性审查旨在整合有关胆和AD的证据,为潜在的建议提供信息.
- 这些发现将指导有关未来随机对照试验的决策,并为患有AD或认知衰退的个体提供先进的营养护理.
更多相关视频
09:45Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
Published on: March 22, 2016
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
相关概念视频
Alzheimer's Disease: Treatment
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Role of Neurotransmitters in Memory
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Direct-Acting Cholinergic Agonists: Pharmacokinetics
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
